ARTICLE | Emerging Company Profile

ReNAgade: getting RNA therapies outside the liver

Over $300M in series A funding gives the RNA medicines company enough capital to reach the clinic

May 23, 2023 11:38 PM UTC

With one of the year’s biggest series A rounds, ReNAgade emerged from stealth Tuesday to develop an RNA platform to code, edit and insert genetic information in vivo while solving a key issue plaguing nanoparticle-based delivery: delivery to tissues outside the liver.

MPM Capital and F2 Ventures led the $300 million round, with participation from  BioImpact Capital and Alexandria Venture Investments...